Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Br J Haematol
; 141(5): 716-9, 2008 May.
Article
en En
| MEDLINE
| ID: mdl-18341631
ABSTRACT
This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0.001) and plasminogen activator inhibitor-1 (PAI-1) levels (P = 0.022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0.024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Polimorfismo Genético
/
Trombosis
/
Síndrome de Behçet
/
Inhibidor 1 de Activador Plasminogénico
/
Carboxipeptidasa B2
Tipo de estudio:
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Haematol
Año:
2008
Tipo del documento:
Article
País de afiliación:
España